## Prescriber Criteria Form

## Tukysa 2025 PA Fax 3781-A v2 010125.docx Tukysa (tucatinib) Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673.** Please contact CVS Caremark at 1-866-785-5714 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Tukysa (tucatinib).

Drug Name:

| Patient Name:       |                 |              |  |  |
|---------------------|-----------------|--------------|--|--|
| Patient ID:         |                 |              |  |  |
| Patient DOB:        | Patient Phone:  |              |  |  |
| Prescriber Name:    |                 |              |  |  |
| Prescriber Address: |                 |              |  |  |
| City:               | State:          | Zip:         |  |  |
| Prescriber Phone:   | Prescriber Fax: |              |  |  |
| Diagnosis:          | ICD Code(s):    | ICD Code(s): |  |  |

| Please circle the appropriate answer for each question. |   |     |    |  |  |
|---|---|-----|----|--|--|
| 1   | Does the patient have a diagnosis of breast cancer? [If no, then skip to question 4.]   | Yes | No |  |  |
| 2   | Does the patient have recurrent, advanced unresectable, or metastatic disease (includes brain metastases)? [If no, then no further questions.]                          | Yes | No |  |  |
| 3   | Does the patient have human epidermal growth factor receptor 2 (HER2)-positive breast cancer? [No further questions.]   | Yes | No |  |  |
| 4   | Does the patient have a diagnosis of advanced, unresectable or metastatic colorectal cancer (including appendiceal adenocarcinoma)? [If no, then no further questions.] | Yes | No |  |  |
| 5   | Has the patient been previously treated with a human epidermal growth factor 2 (HER2) inhibitor?  [If yes, then no further questions.]                                  | Yes | No |  |  |
| 6   | Is the requested drug being used in combination with trastuzumab? [If no, then no further questions.]   | Yes | No |  |  |

| 7      | Does the patient have RAS wild-type, human epic positive disease?  | lermal growth factor receptor 2 (HER2)- | Yes   | No |
|--------|--|---|-------|----|
| Commo  | ents:  |   |       |    |
| , ,    | ning this form, I attest that the information provided is entation supporting this information is available for re |   | t the |    |
| Prescr | iber (or Authorized) Signature:  | Date:                                   |       |    |